Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. (September 2021)

• Record Type: Journal Article
• Authors: Benjamin, Laura A.; Paterson, Ross W.; Moll, Rachel; Pericleous, Charis; Brown, Rachel; Mehta, Puja R.; Athauda, Dilan; Ziff, Oliver J.; Heaney, Judith; Checkley, Anna M.; Houlihan, Catherine F.; Chou, Michael; Heslegrave, Amanda J.; Chandratheva, Arvind; Michael, Benedict D.; Blennow, Kaj; Vivekanandam, Vinojini; Foulkes, Alexander; Mummery, Catherine J.; Lunn, Michael P.; Keddie, Stephen; Spyer, Moira J.; Mckinnon, Tom; Hart, Melanie; Carletti, Francesco; Jäger, Hans Rolf; Manji, Hadi; Zandi, Michael S.; Werring, David J.; Nastouli, Eleni; Simister, Robert; Solomon, Tom; Zetterberg, Henrik; Schott, Jonathan M.; Cohen, Hannah; Efthymiou, Maria;
• Is Part Of: EClinicalMedicine. Volume 39(2021)
• Publication Date: 2021-09
• Subjects: Medicine -- Research -- Periodicals; Medical policy -- Periodicals; Clinical Medicine; Health Policy; Public Health; Medical policy; Medicine -- Research; Periodical; Electronic journals; Periodicals; 613
• DOI: 10.1016/j.eclinm.2021.101070
• Languages: English
• ISSNs: 2589-5370

Abstract

Abstract: Background: A high prevalence of antiphospholipid antibodies has been reported in case series of patients with neurological manifestations and COVID-19; however, the pathogenicity of antiphospholipid antibodies in COVID-19 neurology remains unclear. Methods: This single-centre cross-sectional study included 106 adult patients: 30 hospitalised COVID-neurological cases, 47 non-neurological COVID-hospitalised controls, and 29 COVID-non-hospitalised controls, recruited between March and July 2020. We evaluated nine antiphospholipid antibodies: anticardiolipin antibodies [aCL] IgA, IgM, IgG; anti-beta-2 glycoprotein-1 [aβ2 GPI] IgA, IgM, IgG; anti-phosphatidylserine/prothrombin [aPS/PT] IgM, IgG; and anti-domain I β2 GPI (aD1β2GPI) IgG. Findings: There was a high prevalence of antiphospholipid antibodies in the COVID-neurological (73.3%) and non-neurological COVID-hospitalised controls (76.6%) in contrast to the COVID-non-hospitalised controls (48.2%). aPS/PT IgG titres were significantly higher in the COVID-neurological group compared to both control groups ( p < 0.001). Moderate-high titre of aPS/PT IgG was found in 2 out of 3 (67%) patients with acute disseminated encephalomyelitis [ADEM]. aPS/PT IgG titres negatively correlated with oxygen requirement (FiO2 R =-0.15 p = 0.040) and was associated with venous thromboembolism ( p = 0.043). In contrast, aCL IgA ( p < 0.001) and IgG ( p < 0.001) was associated with non-neurological COVID-hospitalised controls compared to the other groups and correlated positively with d -dimer and creatinine but negatively with FiO2 . Interpretation: Our findings show that aPS/PT IgG is associated with COVID-19-associated ADEM. In contrast, aCL IgA and IgG are seen much more frequently in non-neurological hospitalised patients with COVID-19. Characterisation of antiphospholipid antibody persistence and potential longitudinal clinical impact are required to guide appropriate management. Funding: This work is supported by UCL Queen Square Biomedical Research Centre (BRC) and Moorfields BRC grants (#560441 and #557595). LB is supported by a Wellcome Trust Fellowship (222102/Z/20/Z). RWP is supported by an Alzheimer's Association Clinician Scientist Fellowship (AACSF-20-685780) and the UK Dementia Research Institute. KB is supported by the Swedish Research Council (#2017-00915) and the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and theUK Dementia Research Institute at UCL. BDM is supported by grants from the MRC/UKRI (MR/V007181/1), MRC (MR/T028750/1) and Wellcome (ISSF201902/3). MSZ, MH and RS are supported by the UCL/UCLH NIHR Biomedical Research Centre and MSZ is supported by Queen Square National Brain Appeal.